Author: Renegade_Rcih

Greetings I'm Renegade Rich, I own lots of websites and domain names. one of my favorite news type of sites are news sites. So I own lots of news sites and news domain names. My lates is https://news.post.in 😁

Ecuador to shut down for two days as severe drought sparks electricity crisis and long power cuts

(18 Apr 2024) RESTRICTION SUMMARY: ASSOCIATED PRESS Azuay, Ecuador – 17 April 2024 1. Various of the Mazar dam located…

China expresses ‘grave concerns’ over US deployment of mid-range missile system in Pacific

(18 Apr 2024) RESTRICTION SUMMARY: ASSOCIATED PRESS Beijing – 18 April 2024 1. Wide of Chinese Foreign Ministry spokesperson Lin…

Iranian President Ebrahim Raisi visits Pakistan | DW News

Iranian President Ebrahim Raisi is on a three day visit to Pakistan. It’s the first overseas trip by the Iranian…

Currie: Commodities a ‘Win-Win’ Even If Rates Stay High

Carlyle Group’s chief strategy officer of energy pathways, Jeff Currie, said commodities are going through a consolidation period, meaning they…

JPMorgan Says US Growth Outlook Is a Good Backdrop for Risk Taking

JPMorgan’s Thushka Maharaj says she is optimistic about the US growth situation, which makes it "a very constructive environment for…

Goldman Adding Dealmakers in Paris as Financial M&A Grows

Goldman Sachs has relocated its head of dealmaking for financial institutions in Europe, the Middle East and Africa to Paris…

US Sues to Block $8.5 Billion Tapestry-Capri Luxury Deal

The US Federal Trade Commission sued to stop Tapestry’s $8.5 billion takeover of rival Capri Holdings, saying the acquisition would…

Bloomberg Brief: What to Watch (04/23/24)

Manus Cranny and Dani Burger set the stage for what to watch today. ——– More on Bloomberg Television and Markets…

Daybreak: Middle East & Africa 04/23/2024

Daybreak Middle East & Africa is your daily spotlight on one of the world’s fastest-growing regions. Live from Dubai, we…

Novartis CEO: Broadly Positive About Business Momentum

Novartis CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches….